Drug targeting by retrometabolic design: Soft drugs and chemical delivery systems

Journal of Receptor and Signal Transduction Research

Volumn 21, Issue 2-3, 2001, Pages 287-310

  Bodor, N ^a   Buchwald, P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 0035188964     PISSN: 10799893     EISSN: None     Source Type: Journal    
DOI: 10.1081/RRS-100107431     Document Type: Review

References (130)

1. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents
2. The challenge of liposome targeting in vivo
3. Biological approaches to the controlled delivery of drugs: A critical review
4. Potential and limitations of drug targeting: An overview
5. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers
6. Drug targeting systems for antiviral agents: Options and limitations
7. Themed issue. Targeting of drugs and delivery systems
8. Site-specific drug delivery
9. Theory and practice of site-specific drug delivery
10. A new method for the estimation of partition coefficient
11. Neural network studies. 1. Estimation of the aqueous solubility of organic compounds
12. An extended version of a novel method for the estimation of partition coefficients
13. A new method for the estimation of the aqueous solubility of organic compounds
14. Molecular size based approach to estimate partition properties for organic solutes
15. Octanol-water partition of nonzwitterionic peptides: Predictive power of a molecular size based model
16. Molecular size-based model to describe simple organic liquids
17. Octanol-water partition: Searching for predictive models
18. Computer-aided design of new drugs based on retro-metabolic concepts
19. Computational approaches to the design of safer drugs and their molecular properties
20. Design of biologically safer chemicals
21. Computer assisted design of new drugs based on retrometabolic concepts
22. The role of computational techniques in retrometabolic drug design strategies
23. Novel approaches for the design of membrane transport properties of drugs
24. Soft drugs: Strategies for design of safer drugs
25. Novel approaches to the design of safer drugs: Soft drugs and site-specificchemical delivery systems
26. The soft drug approach
27. Soft drugs
28. Drug targeting via retrometabolic approaches
29. Soft drugs. 1. Labile quaternary ammonium saltsas soft antimicrobials
30. Soft drugs. 2. Soft alkylating compounds as potentialantitumor agents
31. Soft drugs. 3. A newclass of anticholinergic agents
32. Designing safer drugs based on the soft drug approach
33. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds
34. Hepatic cytochrome P-450-linked drug-metabolizing systems
35. Effect of a novel soft steroid on the wound healing of rabbitcornea
36. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate
37. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes
38. Lipophilicity, solubility and permeability of loteprednol etabonate: A novel, soft anti-inflammatory corticosteroid
39. Novel soft steroids: Effects on cell growth in vitro and on wound healing in the mouse
40. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits
41. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate
42. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs
43. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids
44. Soft drugs. 18, Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats-for safer treatment of gastrointestinal inflammation
45. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats
46. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea
47. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis
48. Intraocular pressure response to loteprednol etabonate in known steroid responders
49. Loteprednol etabonate: Comparison with other steroids in two models of intraocular inflammation
50. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
51. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis
52. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
53. A randomized, double-masked, placebo-controlled parallel study of 0.2%loteprednol etabonate in patients with seasonal allergic conjunctivitis
54. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration
55. Change in intraocular pressure during long-term use of loteprednol etabonate
56. The application of soft drug approaches to the design of safer corticosteroids
57. Design of novel soft corticosteroids
58. Regioselectivc O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1′-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function
59. Steroid-induced cataract: New perspectives from in vitro and lens culture studies
60. Uber die bildung eines aminozuckers aus d-fruktose und ammoniak
61. Formation of covalent adducts between cortisol and 16α-hydmxyestrone and protein: Possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus
62. Glucocorticoidlens protein adducts in experimentally induced steroid cataracts
63. Corticosteroid-induced cataracts
64. Soft drugs: Principles and methods for the design of safe drugs
65. Prodrugs versus soft drugs
66. Designing safer ophthalmic drugs
67. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation
68. Problems of delivery of drugs to the brain
69. Redox drug delivery systems for targeting drugs to the brain
70. Chemical delivery systems
71. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems
72. Prodrugs and site-specific chemical delivery systems
73. Themed issue. Low molecular weight prodrugs
74. New methods of drug targeting
75. Drug targeting and retrometabolic drug design approaches
76. Retrometabolic drug design concepts in ophthalmic target-specific drugdelivery
77. Targeting drugs to the brain by sequential metabolism
78. A strategy for delivering peptides into the central nervous system by sequential metabolism
79. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs
80. Molecular packaging: Peptide delivery to the central nervous system by sequential metabolism
81. Brain-targeted delivery of a leucine-enkephalinanalogue by retrometabolic design
82. Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue
83. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds
84. Optimization of the properties of brain specific chemical delivery systemsby structural modifications
85. Targeted drug delivery to the brain via phosphonate derivatives. I. Design, synthesis, and evaluation of an anionic chemical delivery system for testosterone
86. Targeted drug delivery to the brain via phosphonate derivatives. II. Anionic chemical delivery system for zidovudine (AZT)
87. The nicotinamide nucleotide transhydrogenases
88. Physiological roles of nicotinamide nucleotide transhydrogenase
89. Reactivity of biologically important reduced pyridines. Part III. Energetics and mechanism of hydride transfer between 1-methyl-1,4-dihydronicotinamide and the 1-methylnicotinamide cation, a theoretical study
90. A dihydropyridine conjugate which generates high and sustained levels of the corresponding pyridinium salt in the brain does not exhibit neurotoxicity in cynomolgus monkeys
91. Elimination of a quaternary pyridinium salt delivered as its dihydropyridine derivative from brain of mice
92. A dihydropyridine carrier system for sustained delivery of 1′, 3′-dideoxynucleosides to the brain
93. Chemical delivery system to transport a pyroglutamyl peptide to the central nervous system
94. All in the mind
95. Strategies to target kyotorphinanalogues to the brain
96. Medicinal applications of cyclodextrins
97. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins
98. Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxy-propyl-β-cyclodextrin
99. Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery system
100. Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-β-cyclodextrin
101. Cardiovascular complications of oral contraceptives
102. Oral contraceptives, lipids and cardiovascular disease
103. Benefits and risks of estrogen replacement therapy
104. Molecular mechanism of estrogen carcinogenesis
105. Therapeutic considerations in the management of the climacteric
106. Role of female gonadal hormones in the CNS: Clinical andexperimental aspects
107. Estrogen therapy in postmenopausal women - Effects on cognitive function and dementia
108. Outsmarting Alzheimer's disease
109. The interaction of C-17 esters ofestradiol with the estrogen receptor
110. Improved delivery through biological membranes. XXII. Synthesis and distribution of brain-selective estrogen delivery systems
111. Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion
112. Evidence for the reestablishment of copulatory behavior in castrated male rats with a brain-enhanced estradiol-chemical delivery system
113. A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats
114. A redox system for brain targeted estrogendelivery causes chronic body weight decrease in rats
115. Effects of a brain enhanced chemical delivery system for estradiol on body weight and serum hormones in middle-aged male rats
116. Improved delivery through biological membranes. XXXII. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives
117. High performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration in rats
118. Chronic weight loss in lean and obese rats with a brain-enhanced chemical delivery system for estradiol
119. Effects of a brain-enhanced chemical delivery system for estradiol on body weight and food intake in intact and ovariectomized rats
120. Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17β in female rats
121. Brain-targeted delivery of estrogens
122. Effect of molecular manipulation on the estrogenic activity of a brain-targeting estradiol chemical delivery system
123. Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain
124. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat
125. 17β-estradiol attenuates fimbrial lesion-induced decline of CHAT-immunoreactive neurons in the rat medial septum